ACADIA PHARMACEUTICALS INC. Restricted Cash and Cash Equivalents
ACADIA PHARMACEUTICALS INC. (ACAD) had Restricted Cash and Cash Equivalents of $2.83 million as of 2018-03-31, per its 10-Q filed 2018-05-04.
Discontinued › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2018-05-04
- 2018-03-31: Restricted Cash and Cash Equivalents $2.83M.
- 2017-12-31: Restricted Cash and Cash Equivalents $2.48M.
- 2017-09-30: Restricted Cash and Cash Equivalents $2.48M.
- 2017-06-30: Restricted Cash and Cash Equivalents $2.48M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2018-03-31 | $2.83M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $2.48M 10-Q · filed 2018-05-04 |
| 2017-09-30 | $2.48M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $2.48M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $2.48M 10-Q · filed 2018-05-04 |
| 2016-12-31 | $2.38M 10-Q · filed 2018-05-04 |
| 2016-09-30 | $2.38M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $2.38M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $375.00K 10-Q · filed 2016-05-05 |
| 2015-12-31 | $375.00K 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |